Recruiting Alzheimers Disease Studies in New Brunswick
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
This hybrid implementation-effectiveness trial will evaluate Mindfulness-Oriented Recovery Enhancement (MORE) for patients with opioid use disorder receiving methadone treatment (MT). The investigator...
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake...
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase ...
Assessing Optimal XRB Initiation Points in Jail
This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Cor...
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clini...
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS)...
About Alzheimers Disease Clinical Trials in New Brunswick
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 7 alzheimers disease clinical trials recruiting participants in New Brunswick, NJ. These studies are seeking a combined 1,730 participants. Research is being sponsored by Rutgers, The State University of New Jersey, Janssen Research & Development, LLC, Dragonfly Therapeutics and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in New Brunswick — FAQ
Are there alzheimers disease clinical trials in New Brunswick?
Yes, there are 7 alzheimers disease clinical trials currently recruiting in New Brunswick, NJ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New Brunswick?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Brunswick research site will contact you about next steps.
Are clinical trials in New Brunswick free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Brunswick studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 7 active trials in New Brunswick are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov